

Curriculum Vitae
Christina Musgrave, MFS

Signature: 
Date Signed: 30 JUN 2008

Business Address:

CAMC Health Education and
Research Institute
Clinical Trials Center
3100 MacCorkle Avenue, SE
Suite 306
Charleston, WV 25304
Phone: (304) 388-9679
Fax: (304) 388-9935
Email: christina.musgrave@camc.org

EDUCATION:

- 2001 - 2003 Master of Forensic Science (MFS)
The George Washington University
Washington, DC
- 1996 - 2000 Bachelor of Science
(Major: Biology) (Minors: Chemistry, History, and Psychology)
West Virginia Wesleyan College
Buckhannon, WV
- 1996 Diploma
South Charleston High School
South Charleston, WV

PROFESSIONAL EXPERIENCE:

- 2004 - Present Clinical Research Coordinator
CAMC Health Education and Research Institute
Charleston, WV
- 2004 - 2004 Project Specialist
Consolidated Safety Services, Inc.
Fairfax, VA
- 2001 - 2004 Consumer Safety Officer
Food and Drug Administration contracted by Consolidated Safety Services, Inc.
Rockville, MD
- 2001 - 2001 Research Coordinator
WVU Physicians of Charleston, Dept of OB/GYN
Charleston, WV

PROFESSIONAL AFFILIATIONS:

Association of Clinical Research Professionals - 2007

CERTIFICATIONS:

Basic Life Support – 2006

CITI – Course in The Protection of Human Research Subjects – 2005

Conducting Clinical Research Seminar – 2005

Transportation of Dangerous Goods – 2005 / 2008

GCP Guideline-Conduction a Clinical Research Study 2-day Training – 2005

NCCLS Venipuncture and Skin Puncture Procedures /Phlebotomy Skills Training – 2005

The Diabetes Epidemic Workshop by PESI Health Care – 2005

CAMC HIPPA Awareness and Guidelines – 2004

Clinical Research Associates Training (Internet) – 2004

Human Subjects Protection Education and Training – 2004

Various other CAMC training inc. blood-born pathogens, infectious diseases, patient confidentiality, and Biohazard waste – 2004

Various other Forensic Science related training – 2004-2003

CLINICAL RESEARCH EXPERIENCE:

4 Years of Research Experience to date

Clinical Research Coordinator: the primary role of the Research Coordinator is to screen and assess the patients in accordance with the protocol for eligibility, baseline, and follow-up procedures. The research coordinator is also responsible for assisting in the informed consent process, completing all case report forms, collecting the data, and maintaining documents and correspondence with the sponsor. The coordinator also completes all internal and external regulatory requirements.

HS# *DCRI* - Bivalirudin PCI Registry in HIT/HITTS Patients, *Medicines Company*

HS# *EXOS* - Exenatide Observational Study in the U.S., *Eli Lilly and Company*

HS# 08-06-2054: *DVT* - Protocol Title: Protocol B0661001 – CV185056: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism, *Pfizer, Inc*

HS# 08-04-2049: *ZESCA* - Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome, *Canadian Institutes of Health Research*

HS# 07-10-1980: *VIVUS 303* - A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults with Obestiy-Related Co-Morbid Conditions, *VIVUS Inc*

HS# 07-10-1979: *VIVUS 302* - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adult Population with BMI greater than or equal to 35, *VIVUS Inc*

HS# 07-07-1962: *TMC 125 HIV* - Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment Options, *Tibotec Pharmaceuticals Ltd.*

HS# 07-04-1926: *Merck HIV* - Early Access of MK-0518 in Combination with an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV Infected Patients with Limited to No Treatment Options, *Merck & Co, Inc*

HS# 07-03-1920: *QAB* - A 26-week Treatment, Multi-center, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of Indacaterol (selected from 75, 150, 300, and 600 mg o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12mg b.i.d.) and Open Label Tiotropium (18 mg o.d.) as Active Controls, *Novartis Pharmaceuticals Inc*

HS# 07-02-1908: *PEDS # 2 1-5* - A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal period, *Novartis*

HS# 07-02-1907: *PEDS # 2 1-5 Extension* - An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension, *Novartis*

HS# 07-02-1905: *MARAVIROC* - Protocol Number A4001050 - A Multicenter, Open Label, Expanded Access Trial of Maraviroc, *Pfizer, Inc*

HS# 07-01-1894: *PEDS # 2 6-17 Extension* - Protocol Number CVAL489K2302 E01: A 14 week Extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long-term safety, tolerability and efficacy of valsartan and enalapril combined and alone in children 6 to 17 years of age with hypertension, *Novartis*

HS# 07-01-1893: *PEDS # 2 6-17* - Protocol Number CVAL489K2302: A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertension, *Novartis*

HS# 06-06-1825: *PEDS 6-17* - Protocol Number CVAL489K2301: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Effect of Valsartan on Proteinuria and Glomerular Filtration Rate in Children with Chronic Kidney Disease Who are Receiving a Standardized Dose of Angiotensin Converting Enzyme Inhibitor Therapy, *Novartis Pharmaceuticals*

HS# 06-04-1797: *VIVA I / XCELL* - Protocol Number 00-105-644: Xpert™ Nitinol Stenting for Critically Ischemic Lower Limbs, *VIVA I Physicians, Inc*

HS# 06-05-1821: *PEDIATRIX NICU* - Demographic, Metabolic, and Genomic Description of Neonates with Severe Hyperbilirubinemia, *Pediatric Medical Group*

HS# 06-05-1812: *HERMES* - Protocol Number BY 217/M2-125: Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease- A 52-Weeks, Double-blind Study with 500mcg Roflumilast Once Daily versus Placebo, *ALTANA, Pharma US, Inc*

HS# 06-04-1799: *PANTOPRAZOLE* - Protocol Number 3001B3-328-NA: A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5, with Endoscopically Proven Symptomatic GERD, *Wyeth Research*

HS# 06-03-1782: *IDA U* - Protocol Number H7U-MC-IDA U: A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIPP) Compared to Preprandial Injectable Insulin-Naive Patients with Type 2 Diabetes Mellitus, *Eli Lilly and Company*

HS# 06-02-1776: *SONDIKE PEDS* - The Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents with Type 2 Diabetes, *The Dr. Robert C. Atkins Foundation*

HS# 06-01-1761: *EXUBERA* - An International, Multicenter, Large Simple Trial to Evaluate the Long-Term Pulmonary and Cardiovascular Safety of Exubera(R) in Patients with Diabetes Mellitus, *Pfizer, Inc*

HS# 05-09-1727: *RSV* - Protocol Number MI-CP116: A Phase IV, Randomized, Double-Blind, Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis (R)) in Children at High Risk for Development of Serious RSV Disease, *MedImmune, Inc*

HS# 05-09-1726: *IGF1* - Protocol Number MS301: Recombinant Human Insulin-Like Growth Factor-1 Treatment of Prepubertal Children with Growth Failure Associated with Primary IGF-1 Deficiency: A Phase III, Randomized, Open-Label, Observation Controlled, Multi-Center, Parallel Dose Comparison Trial, *Tercica, Inc*

HS# 05-08-1714: *ALVIMOPAN 014* - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Therapy, *GlaxoSmithKline*

HS# 05-08-1713: *ALVIMOPAN 013* - A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain, *GlaxoSmithKline*

HS# 04-10-1642: *ANA* - External Continuous Subcutaneous Infusion of Insulin Aspart (NovoLog(R)) versus Insulin Lispro (Humalog(R)): An Open-Label, Randomized, Parallel Group, Multicenter Study in Children and Adolescents with Type I Diabetes, *Novo Nordisk*

HS# 04-01-1557: *PEDS 1-5* - A Double-Blind, Randomized, Multi-Center Study Followed by 12 Months Open-Label Treatment to Evaluate the Dose-Response and Safety of Valsartan in Pediatric Hypertensive Patients 1 - 5 Years of Age, *Novartis*

HS# 03-08-1509: *PEDS 261B* - Protocol Number 261B: Protocol 261B: A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age, *Astra Zeneca*

HS# 03-08-1508: *PEDS 261A* - Protocol Number 261A: A Dose Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, *Astra Zeneca*

HS# 02-11-1426: *PEDS 1-5* - Protocol Number Protocol # CVAL489 A2302: A Double-Blind, Randomized, Multicenter Study followed by 12 Months Open-label Treatment to Evaluate the Dose-response and Safety of Valsartan in Pediatric Hypertensive Patients, *Novartis*

HS# 01-07-1290: *GWSK TORCH* - Protocol Number SCO30003: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of

Salmeterol/Fluticasone Propionate (Seretide/Viani/Advair) 50/500ug bd, Salmeterol 50ug bd and Fluticasone Propionate 500 ug bd, All Delivered via the Diskus/Accuhaler Inhaler, on the Survival of Subjects with Chronic Obstructive Pulmonary Disease (COPD) over 3 Years of Treatment, *Glaxo Wellcome R & D*

+++ HS# is Internal study Identifier